m+Medelevator.RU
← Поиск публикаций
Cancer biology & medicine · 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Consensus StatementСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Guo Zhenying, Xu Chunwei, Zhang Shirong, Hao Yue, Hu Xiaotong, Zhao Ming, Xiang Chan, Piao Yingshi, Sun Pingli, Xiang Xueping, Zhao Jing, Wu Huanwen, Li Weixing, Yu Jinpu, Yuan Jingping, Wang Shuangshuang, Wang Cong, Gu Yun, Lv Bingjian, Zhang Liping, Liu Yueping, Cui Xiaobin, Gu Weizhong, Li Yining, Wang Wei, Yang Wenjun, Long Weiguo, Xiang Jingjing, Mou Hong, Liu Biao, Ruan Huajuan, Wang Yubin, Zhu Yongjie, Wang Feng, Wang Zhonghua, Feng Xiaomin, Liu Xing, Li Peng, Deng Min, Lian Bin, Mao Lili, Wang Qian, Wang Wenxian, Song Zhengbo, Li Ziming, Zhong Wenzhao, Wang Zhijie, Ren Shengxiang, Fang Wenfeng, Zhang Yongchang, Liu Jingjing, Cai Xiuyu, Liu Anwen, Li Wen, Zhan Ping, Liu Hongbing, Lv Tangfeng, Miao Liyun, Min Lingfeng, Chen Yu, Zhang Yu, Wang Feng, Jiang Zhansheng, Lin Gen, Huang Long, Pu Xingxiang, Lin Rongbo, Liu Weifeng, Rao Chuangzhou, Lv Dongqing, Yu Zongyang, Shen Peng, Li Xiaoyan, Tang Chuanhao, Zhou Chengzhi, Zhang Junping, Xue Junli, Guo Hui, Chu Qian, Meng Rui, Wu Jingxun, Zhang Rui, Zhou Jin, Zhu Zhengfei, Li Yongheng, Qiu Hong, Xia Fan, Lu Yuanyuan, Chen Xiaofeng, Ge Rui, Dai Enyong, Han Yu, Zhang Jian, Ji Yinghua, Liang Xianbin, Zhang Hongmei, Ma Xuelei, Liu Xuewen, Yao Yu, Luo Peng, Pan Weiwei, Pang Fei, Wu Fan, Gu Dejian, Wang Li, Wang Liping, Zhu Youcai, Lin Li, Li Weiwen, Lin Xinqing, Cai Jing, Xu Ling, Li Jisheng, Jiao Xiaodong, Li Kainan, Wei Jia, Feng Huijing, Wang Lin, Du Yingying, Yao Wang, Shi Xuefei, Niu Xiaomin, Yuan Dongmei, Yao Yanwen, Zhang Yinbin, Song Binbin, Li Wenfeng, Fu Jianfei, Wang Hong, Ye Mingxiang, Wang Dong, Wang Zhaofeng, Ji Qing, Fang Yuan, Wei Qing, Wang Zhen, Wan Bin, Lv Donglai, Li Xiaofeng, Yang Shengjie, Kang Jing, Zhang Jiatao, Zhang Chao, Shi Lin, Wang Yina, Li Bihui, Zhang Zhang, Wang Ke, Liu Zhefeng, Yang Nong, Wu Lin, Chen Xiaobing, Jin Gu, Li Zhongwu, Li Miao, Wang Guansong, Wang Jiandong, Fang Meiyu, Fang Yong, Wang Xiaojia, Chen Jing, Zhang Yiping, Zhu Xixu, Shen Yi, Ma Shenglin, Wang Biyun, Si Lu, Song Yong, Lu Yuanzhi, Liu Aijun, Han Yuchen

Аннотация

As an emerging biomarker, tumor mutational burden (TMB) has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy. Currently, TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms. However, the lack of uniformity in detection methods, threshold settings, and reporting formats, as well as the significant differences in TMB values among different cancer types, have hindered the standardized application of this biomarker in clinical practice. This consensus focuses on the definition, standardization of detection, clinical significance, and limitations of TMB, and provides consensus recommendations for the clinical application of TMB in real-world practice in China. This consensus is aimed at helping clinicians and laboratory personnel understand the clinical significance and testing standards of TMB, promoting more accurate interpretation of test results, and improving patient care.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты